Effect of statins in preventing contrast-induced nephropathy: An updated meta-analysis

Coronary Artery Disease

Volumn 25, Issue 7, 2014, Pages 565-574

  Xie, Hongzhi ^a   Ye, Yicong ^a   Shan, Guangliang ^b   Zhang, Shuyang ^a   Fang, Quan ^a   Yang, Deyan ^a   Zeng, Yong ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Contrast induced nephropathy; Meta analysis; Statins

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; CONTRAST MEDIUM;

ARTICLE; CAUSE OF DEATH; COCHRANE LIBRARY; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MEGADOSE; EMBASE; HUMAN; LOW DRUG DOSE; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; RISK FACTOR; ACUTE KIDNEY INJURY; CHEMICALLY INDUCED; CHEMOPROPHYLAXIS;

ACUTE KIDNEY INJURY; CHEMOPREVENTION; CONTRAST MEDIA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 84927696254     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0000000000000148     Document Type: Article

References (43)

1. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996;275:1489-1494.
2. James MT, Samuel SM, Manning MA, Tonelli M, Ghali WA, Faris P, et al. Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography: a systematic review and meta-analysis. Circ Cardiovasc Interv 2013;6:37-43.
3. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-375.
4. Sun Z, Fu Q, Cao L, Jin W, Cheng L, Li Z. Intravenous n-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials. PloS One 2013;8:e55124.
5. ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized acetylcysteine for contrast-induced nephropathy trial (act). Circulation 2011;124:1250-1259.
6. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 2008;148:284-294.
7. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002;39:930-936.
8. Attallah N, Yassine L, Musial J, Yee J, Fisher K. The potential role of statins in contrast nephropathy. Clin Nephrol 2004;62:273-278.
9. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-269, W264.
10. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
11. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
12. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making 2013;33:607-617.
13. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010;29:932-944.
14. Ye Y, Xie H, Zeng Y, Zhao X, Tian Z, Zhang S. Optimal oral antithrombotic regimes for patients with acute coronary syndrome: a network meta-analysis. PloS One 2014;9:e90986.
15. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-1101.
16. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.
17. Jo SH, Koo BK, Park JS, Kang HJ, Cho YS, Kim YJ, et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial 9 a randomized controlled study. Am Heart J 2008;155:499.e1-499.e8.
18. Chen GL, Su JZ. Atorvastatin attenuated contrast induced renal function damage. Zhonghua Xin Xue Guan Bing Za Zhi 2009;37:389-393.
19. Xinwei J, Xianghua F, Jing Z, Xinshun G, Ling X, Weize F, et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrastinduced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 2009;104:519-524.
20. Zhou X, Jin YZ, Wang Q, Min R, Zhang XY. Efficacy of high dose atorvastatin on preventing contrast induced nephropathy in patients underwent coronary angiography. Zhonghua Xin Xue Guan Bing Za Zhi 2009;37:394-396.
21. Acikel S, Muderrisoglu H, Yildirir A, Aydinalp A, Sade E, Bayraktar N, et al. Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography. Blood Coagul Fibrinolysis 2010;21:750-757.
22. Ozhan H, Erden I, Ordu S, Aydin M, Caglar O, Basar C, et al. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology 2010;61:711-714.
23. Toso A, Maioli M, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, et al. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol 2010;105:288-292.
24. Yu DJ, Su JZ, Chen GL, Cai WQ, Jin XQ, Chai DJ. Effect of different doses of atorvastatin in contrast-induced nephropathy. Chin J Interv Imaging Ther 2010;7:520-524.
25. Lu Y, Zhao X, Qin Y. Clinical research on efficacy of statins in preventing contrast-induced nephropathy. Pharm Care Res 2011;11:111-114.
26. Patti G, Ricottini E, Nusca A, Colonna G, Pasceri V, D'Ambrosio A, et al. Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy inpatients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty - contrast-induced nephropathy] trial). Am J Cardiol 2011;108:1-7.
27. Cao S, Wang P, Cui K, Zhang L, Hou Y. Atorvastatin prevents contrast agentinduced renal injury in patients undergoing coronary angiography by inhibiting oxidative stress. Nan Fang Yi Ke Da Xue Xue Bao 2012;32:1600-1602.
28. De Oliveira MS, Martins KBA, Costa JR Jr, Abizaid A, Stadler J, Mattos LA, et al. Impact on renal function of rosuvastatin preload prior to elective percutaneous coronary intervention in chronic statin users. Rev Bras Cardiol Invasiva 2012;20:303-308.
29. Li W, Fu X, Wang Y, Li X, Yang Z, Wang X, et al. Beneficial effects of highdose atorvastatin pretreatment on renal function in patients with acute STsegment elevation myocardial infarction undergoing emergency percutaneous coronary intervention. Cardiology 2012;122:195-202.
30. Quintavalle C, Fiore D, De Micco F, Visconti G, Focaccio A, Golia B, et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation 2012;126:3008-3016.
31. Kaya A, Kurt M, Tanboga IH, Işik T, Ekinci M, Aksakal E, et al. Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (rosa-cin trial). Acta Cardiol 2013;68:488-494.
32. Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F. Early highdose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the prato-acs study (protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome). J Am Coll Cardiol 2014;63:71-79.
33. Han Y, Zhu G, Han L, Hou F, Huang W, Liu H, et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol 2014;63:62-70.
34. Pappy R, Stavrakis S, Hennebry TA, Abu-Fadel MS. Effect of statin therapy on contrast-induced nephropathy after coronary angiography: a metaanalysis. Int J Cardiol 2011;151:348-353.
35. Zhou Y, Yuan WJ, Zhu N, Wang L. Short-term, high-dose statins in the prevention of contrast-induced nephropathy: a systematic review and metaanalysis. Clin Nephrol 2011;76:475-483.
36. Zhang BC, Li WM, Xu YW. High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis. Can J Cardiol 2011;27:851-858.
37. Takagi H, Umemoto T. A meta-analysis of randomized trials for effects of periprocedural atorvastatin on contrast-induced nephropathy. Int J Cardiol 2011;153:323-325.
38. Zhang L, Zhang L, Lu Y, Wu B, Zhang S, Jiang H, et al. Efficacy of statin pretreatment for the prevention of contrast-induced nephropathy: a metaanalysis of randomised controlled trials. Int J Clin Pract 2011;65:624-630.
39. Zhang T, Shen LH, Hu LH, He B. Statins for the prevention of contrastinduced nephropathy: a systematic review and meta-analysis. Am J Nephrol 2011;33:344-351.
40. Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D, O'Donnell MJ, Moscucci M. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 2005;118:843-849.
41. Patti G, Nusca A, Chello M, Pasceri V, D'Ambrosio A, Vetrovec GW, Di Sciascio G. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol 2008;101:279-285.
42. Al-Otaibi KE, Al Elaiwi AM, Tariq M, Al-Asmari AK. Simvastatin attenuates contrast-induced nephropathy through modulation of oxidative stress, proinflammatory myeloperoxidase, and nitric oxide. Oxid Med Cell Longev 2012;2012:831748.
43. Kwok CS, Pang CL, Yeong JK, Loke YK. Measures used to treat contrastinduced nephropathy: overview of reviews. Br J Radiol 2013;86:20120272.